China Pharmaceutical University Affiliated Chongqing Starry Plastic Surgery Hospital Officially Inaugurated, Marking the Transition of University–Hospital Collaboration from Agreement to Implementation

At the inauguration ceremony, Xinhao Li, Vice President of Fosun Health and General Manager of China Pharmaceutical University Affiliated Chongqing Shinrong Plastic Surgery Hospital, expressed his heartfelt appreciation to government authorities, industry experts, and the entire hospital team for their unwavering support and dedication.

He noted that becoming an affiliated hospital of China Pharmaceutical University marks not the culmination of Shinrong Plastic Surgery Hospital’s achievements, but the beginning of a new chapter—one that calls for even higher standards of medical excellence and a stronger commitment to delivering outstanding care for patients seeking aesthetic treatment.

Looking ahead, the hospital will leverage the university–industry collaboration platform to build an integrated value chain spanning research and development (R&D), technology translation, and commercialization, connecting every stage of the industry from upstream to downstream. Through a long-term strategic approach, Shinrong Plastic Surgery Hospital aims to accelerate the implementation of collaborative initiatives and transform the value of university–industry cooperation into tangible outcomes that drive sustainable industry growth.

* Xinhao Li Vice President of Fosun Health and General Manager of China Pharmaceutical University Affiliated Chongqing Shinrong Plastic Surgery Hospital

On behalf of the Aesthetic and Plastic Surgeons Branch of the Chinese Medical Doctor Association, Professor Jianxing Song, President of the Association and Director of the Department of Plastic Surgery at the Fourth Affiliated Hospital of Tongji University School of Medicine in Shanghai, also conveyed his warm congratulations on the official inauguration of China Pharmaceutical University Affiliated Chongqing Shinrong Plastic Surgery Hospital. Entrusted by Professor Xiaojun Wang, Director of the National Center for Quality Control of Plastic Surgery, Chairman of the Plastic Surgery Branch of the Chinese Medical Association, and Director of the Department of Plastic Surgery at Peking Union Medical College Hospital, Professor Song also extended congratulations on behalf of the Plastic Surgery Branch of the Chinese Medical Association.

Professor Song noted that since its establishment, Shinrong Plastic Surgery Hospital has achieved a series of pioneering milestones among China’s private plastic surgery hospitals. From being accredited as a Grade III Plastic Surgery Hospital upon its opening, to serving as the Chair Institution of the Aesthetics and Cosmetology Branch of the Chinese Medical Association and the editorial office of the Chinese Journal of Medical Aesthetics and Cosmetology, the hospital has consistently demonstrated academic and clinical leadership. It has also published the landmark reference History of Plastic and Aesthetic Surgery in China and received the First Prize of the Science and Technology Award from the Chinese Association of Plastic and Aesthetic Surgery, among numerous other honors. These achievements underscore the hospital’s professional excellence and its commitment to advancing the specialty.

He further emphasized that Shinrong Plastic Surgery Hospital’s designation as an affiliated hospital of China Pharmaceutical University—one of China’s prestigious “211 Project” and “Double First-Class” universities—represents a significant milestone for the country’s plastic surgery sector. It establishes a new model for university–industry collaboration and offers an innovative pathway for the development of privately operated healthcare institutions in China.

*Professor Jianxing Song President, Aesthetic and Plastic Surgeons Branch of the Chinese Medical Doctor Association; Director, Department of Plastic Surgery, Fourth Affiliated Hospital of Tongji University School of Medicine, Shanghai

In his remarks, Qiyu Chen, Co-CEO of Fosun International, stated that the rapid progress from the cooperation agreement signed in Nanjing in May to today’s official inauguration reflects the shared vision and strong strategic alignment between the two partners.

He noted that Shinrong Plastic Surgery Hospital was established during a period of transformation in the aesthetic medicine industry, with the ambition of breaking away from the traditional development model of private healthcare institutions. From its inception, the hospital was built to the standards of a Grade III Plastic Surgery Hospital, with a strong focus on specialty development, clinical and research capabilities, and academic excellence. This commitment has enabled the hospital to pursue a high-quality, innovation-driven development path rooted in academic leadership.

Chen further emphasized that building a global center for clinical innovation in plastic and aesthetic surgery has become the shared strategic vision of both parties through extensive discussions. Leveraging Fosun Pharma’s integrated healthcare ecosystem and full industry-chain capabilities, the university and the enterprise will work together to establish a seamless innovation pipeline—from scientific research and clinical validation to industrial translation and commercialization. This collaboration will accelerate the application of high-quality research outcomes in clinical practice, further enhancing medical technologies and healthcare services.

* Qiyu Chen Co-CEO of Fosun International

In his keynote address, Professor Haiping Hao, President of China Pharmaceutical University, emphasized that this collaboration goes far beyond the designation of an affiliated hospital. It represents a deep integration of shared development philosophies, institutional values, and long-term strategic goals. He remarked that, from this day forward, every member of Shinrong Plastic Surgery Hospital officially becomes part of the China Pharmaceutical University community.

Professor Hao pointed out that, as people’s expectations for quality of life continue to rise, demand for aesthetic medicine and healthy aging solutions is growing rapidly, placing the medical aesthetics industry at a pivotal stage of transformation driven by scientific research and innovation. Building upon the shared vision of establishing a global center for clinical innovation in plastic and aesthetic surgery, he further proposed creating a dual global center for both clinical innovation and novel drug research and development in the field.

By leveraging supportive local government policies, Fosun’s integrated healthcare industry resources, and China Pharmaceutical University’s strengths in pharmaceutical research and talent cultivation, the partnership will accelerate the translation of pharmaceutical research into clinical applications. Professor Hao concluded that this collaboration is founded not only on a shared recognition of Fosun’s strategic vision and industrial capabilities, but also on strong confidence in Shinrong Plastic Surgery Hospital’s professional excellence and commitment to the industry. Together, the two parties will inject new momentum into the standardized, science-driven, and sustainable development of China’s medical aesthetics sector.

*Professor Haiping Hao President, China Pharmaceutical University

During the inauguration ceremony, Professor Haiping Hao, President of China Pharmaceutical University; Professor Yong Yang, Member of the Standing Committee of the CPC Committee and Vice President of China Pharmaceutical University; Qiyu Chen, Co-CEO of Fosun International; and Yuqing Chen, Chairman of Fosun Pharma, jointly took the stage to unveil the plaque for China Pharmaceutical University Affiliated Chongqing Shinrong Plastic Surgery Hospital. The historic moment was witnessed by all distinguished guests in attendance, marking a significant milestone for the development of China’s plastic and aesthetic surgery industry.

*From left to right at the inauguration ceremony: Qiyu Chen, Co-CEO of Fosun International; Professor Haiping Hao, President of China Pharmaceutical University; Yuqing Chen, Chairman of Fosun Pharma; and Professor Yong Yang, Member of the Standing Committee of the CPC Committee and Vice President of China Pharmaceutical University.

China Pharmaceutical University, a national “211 Project” and “Double First-Class” university directly administered by China’s Ministry of Education, is widely recognized as the “Cradle of China’s Biopharmaceutical Talent.” The University possesses outstanding research capabilities and a strong talent pool in areas including innovative drug discovery, pharmacological evaluation, and clinical pharmacy.

Shinrong Plastic Surgery Hospital, the flagship aesthetic medicine hospital of Fosun Health, is Chongqing’s first Grade III Plastic Surgery Hospital. The hospital serves as the training and guidance base for five national academic organizations and was among the earliest private healthcare institutions in China to obtain dual Good Clinical Practice (GCP) accreditation for clinical trials involving both medical aesthetic pharmaceuticals and medical devices, officially approved in 2023. These achievements have established Shinrong as a leader among China’s private aesthetic medicine institutions in academic excellence, clinical research, and standardized hospital management.

By combining the scientific strengths of a world-class pharmaceutical university with the clinical expertise of a Grade III plastic surgery hospital, Shinrong Plastic Surgery Hospital will leverage its new role as an affiliated hospital of China Pharmaceutical University to fully integrate into the University’s academic disciplines, scientific research initiatives, and talent development programs.

Building upon its existing clinical services, the hospital will establish an integrated platform that connects medical care, research, and industrial innovation. Through this platform, university academic resources will further enhance medical education and professional training, while cutting-edge technologies and research methodologies will be introduced to strengthen the integration of clinical practice with basic scientific research. Leveraging Fosun Pharma’s comprehensive industry ecosystem, the hospital will accelerate the commercialization of research achievements and foster the development of innovative technologies and products. At the same time, the University’s academic platform will broaden the hospital’s global perspective, further enhance its academic influence, and reinforce its role as an industry benchmark, providing sustained momentum for high-quality development.